The Anomali Platform Advances Intelligence-Driven Detection and Response Capabilities and Prevents Business Disruptions While Optimizing Security Expense
15.9.2022 02:46:00 EEST | Business Wire | Press release
Anomali, the leader in intelligence-driven cybersecurity solutions, announced the general availability today of its quarterly platform update to meet the expanding needs of its customers and partners. This release introduces new capabilities to enhance Anomali’s threat intelligence and extended detection and response (XDR) use cases that enable enterprise organizations to stay one step ahead of adversaries and prevent business disruptions while optimizing security expenses.
“Anomali’s August release offers new capabilities and enhancements for security operations teams struggling to identify not only who’s targeting them, but how and why they are being targeted,” said Mark Alba, Chief Product Officer at Anomali.
Key highlights of this release include:
Creating Extended Visibility with Anomali Attack Pattern Detection and MITRE ATT&CK®: In 2021, Anomali joined MITRE Engenuity’s Center for Threat-Informed Defense to collaborate on the Attack Flow Project to better understand adversary behavior and improve defensive capabilities. This partnership culminated with the public release of the project in March 2022.
Since then, Anomali has been working to incorporate attack flows into The Anomali Platform. This release moves the platform toward an Attack Flow Library for Anomali ThreatStream that will provide an access point for new Attack Flows that sequence cyberattack techniques. This capability will provide a new context around adversary behavior and help security teams expertly profile the adversary. It will also enable them better to protect the organization in advance of an attack, detect an attack in real-time, and respond post-attack.
Furthermore, this predictive visual mapping will be leveraged by CISOs and security professionals to align attacks with potential holes in their security posture to get in front of the threat.
“ESG research found that 97% of security professionals believe that MITRE ATT&CK is important to their organization’s security operations strategy,” said Jon Oltsik, Senior Principal Analyst and Fellow, ESG Research. “Anomali’s commitment to integrating the MITRE ATT&CK Framework into its solutions and participating in the MITRE Engenuity Center for Threat Informed Defense can help security teams adopt the framework and better understand cyber-adversaries.”
Routine Workflow Automation: Given macro-economic conditions, customers are looking for capabilities that make their existing investments more impactful. We’ve introduced a new extensible framework to support the automation of routine tasks throughout the platform. This release's first implementation is available to automate enrichments in the investigations workbench. A drag-and-drop process for configuring a multi-stage enrichment task can easily be set and run when conditions require it, saving analysts time performing repetitive tasks.
Additional enhancements with this platform release include:
- Support for MITRE ATT&CK Mobile & ICS: Intelligence aggregation, contextualization, and analysis for Mobile and ICS attack surfaces to strengthen overall security posture.
- MITRE ATT&CK Enterprise v11 in Anomali Lens
- Scheduled Retrospective Search: Helps the SOC automate the correlation of historical events with newly available intelligence to produce reports and gain insight into threat actors, TTPs, or other adversary behavior. This new capability enables CISOs to detect real-time threats in their local IT environment.
Anomali will be exhibiting at BlackHat on August 10 & 11, Booth #3034. Stop by to chat with the team and learn more about our intelligence-driven solutions.
About Anomali
Anomali is the leader in intelligence-driven extended detection and response (XDR) cybersecurity solutions. Anchored by big data management (the “X”) and refined by artificial intelligence, The Anomali Platform, an XDR solution, delivers unique proprietary capabilities that correlate the largest repository of global intelligence with telemetry from customer-deployed security solutions. This combination empowers security operations teams to accurately detect threats, optimize response, achieve resiliency, and ultimately stop attackers and breaches. Our SaaS-based solutions easily integrate into existing security tech stacks through native-cloud, multi-cloud, on-premises, and hybrid deployments. Founded in 2013, Anomali serves global B2B enterprise businesses, large public sector organizations, ISACs, ISAOs, service providers, and Global 1000 customers to help safeguard the world’s critical infrastructure, companies, and people. Leading venture firms, including Google Ventures, General Catalyst, and IVP, back Anomali. Learn more at www.anomali.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220808005789/en/
Contact information
Karen Buffo
news@anomali.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening of Clinical Leadership30.4.2026 14:00:00 EEST | Press release
CorFlow Therapeutics AG (CorFlow), a clinical-stage company focused on transforming the diagnosis and treatment for heart attack patients, today announced multiple milestones in advancing its clinical program and the strengthening of clinical leadership. Phase 1 of the company’s MOCA II FDA Pivotal Trial was successfully reached after safety and performance goals were met with STEMI heart attack patients who had the proprietary PCoFI diagnostic measurement of microvascular obstruction (MVO) made during a stenting procedure, when compared to the reference standard diagnosis by cardiac MRI in the subsequent days. Phase 1 included 19 patients enrolled across 5 US and 3 European sites. MOCA II follows the FIH MOCA I study and primarily aims to validate the threshold value of the proprietary PCoFI measurement for diagnosing MVO in the setting of primary angioplasty compared to cardiac MRI. This milestone achievement, which was confirmed by the study’s independent DSMB (Data and Safety Monit
Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint ® and BluePrint ® at the 2026 ESMO Breast Cancer Annual Congress30.4.2026 14:00:00 EEST | Press release
Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new data at the 2026 European Society for Medical Oncology (ESMO) Annual Congress on Breast Cancer, taking place May 6-8 in Berlin, Germany. The company will present two posters featuring data from the prospective FLEX Study and an independent post hoc analysis of the landmark MINDACT trial that underscore the prognostic value of MammaPrint® + BluePrint® in early-stage breast cancer (EBC). Poster #65P | Thursday, May 7, 13:15 – 14:15 p.m. CEST | Presenter: Elena Shagisultanova Prognostic Performance of MammaPrint in Patients with Small T1a, b, and c Node-Negative Early Breast Cancer A retrospective analysis from the FLEX Study involving 4,349 patients highlights the biological heterogeneity within small, node-negative (T1a, b, and c) tumors – a group that typically has favorable outcomes. MammaPrint (MP) identified a High Risk 2 (H2) subset, representing 10% of all patients and 5% of those
The Biggest Predictor of Business Growth Is Behavior30.4.2026 10:00:00 EEST | Press release
IDEO, the global design and innovation company, today announced the IDEO Innovation Quotient (IDEO IQ), a new report measuring how workplace behaviors drive business performance across 100 of the world’s largest companies. Those with the highest IDEO IQ scores earned nearly $20 billion in profit last year—50% higher than average and three times more than those ranked at the bottom. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429978890/en/ The IDEO Innovation Quotient (IDEO IQ) is a new report measuring how workplace behaviors drive business performance across 100 of the world’s largest companies. The IDEO IQ surveyed 266 leaders in product and innovation roles at 100 of the world’s largest companies across the Media & Technology, Healthcare, and Consumer Goods sectors. The report is the first of its kind to draw a direct line between how companies operate internally and their financial performance. Companies were surve
Suzano Sells 12.7 Million Tonnes of Pulp for the First Time in Its History30.4.2026 01:22:00 EEST | Press release
Suzano(B3: SUZB3 | NYSE: SUZ), the world’s largest pulp producer, announces its results for the first quarter of 2026 (1Q26), achieving a new all‑time record in pulp sales. Over the 12‑month period from April 2025 to March 2026, the company sold 12.7 million tonnes of pulp, the highest volume ever recorded in its history. During the same period, Suzano also sold 1.7 million tonnes of paper across the packaging, printing and writing, specialty, and tissue segments. This unprecedented sales level mainly reflects the increase in production capacity following the start‑up of the Ribas do Rio Pardo pulp mill in the state of Mato Grosso do Sul, as well as Suzano’s strong operational efficiency across its production lines and supply chains, serving customers in more than 100 countries worldwide. In the first quarter of 2026, Suzano sold a total of 3.2 million tonnes, comprising 2.8 million tonnes of pulp and 378 thousand tonnes of paper. Net revenue amounted to BRL 11.0 billion, while adjuste
The Estée Lauder Companies Announces Minority Investment in Luxury Clinical Skin Care Brand 111SKIN29.4.2026 23:30:00 EEST | Press release
The Estée Lauder Companies Inc. (NYSE:EL) today announced a minority investment in 111SKIN, a luxury clinical skin care brand founded by renowned plastic and reconstructive surgeon Dr. Yannis Alexandrides. Terms of the investment were not disclosed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429495879/en/ 111SKIN's Reparative Collection Founded in 2012, 111SKIN was originally developed by Dr. Alexandrides to accelerate his patients’ healing time following procedures. At the heart of the brand is its innovative NAC Y2™, a pioneering complex designed to support skin repair and maintain a healthy, radiant and resilient complexion. Building on the foundation of this clinical expertise, 111SKIN has developed a portfolio of more than 30 products, anchored by its Black Diamond and Reparative collections and priced from $50 to $1,000. “Skin care is entering a new phase, shaped by the convergence of procedures, longevity and b
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
